Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SLLN-15 是一个具有口服活性的、选择性的、有效的自噬 (autophagy) 增强剂。SLLN-15 可激活三阴乳腺癌细胞的自噬。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 14,900 | 8-10周 | ||
50 mg | ¥ 19,420 | 8-10周 | ||
100 mg | ¥ 24,625 | 8-10周 |
产品描述 | SLLN-15 is an oral active, selective and potent enhancer of autophagy. SLLN-15 activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) [1]. |
体外活性 | SLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h significantly decreases overall cell viability of breast cancer cells in a dose-dependent manner [1]. SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines [1]. Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling. Cell Viability Assay [1] Cell Line: TNBC cell lines BT-20 and MDA-MB-231. Concentration: 0, 1, 5, 10, 25 μM. Incubation Time: 24 hours. Result: Inhibited the proliferation of two TNBC cell lines, BT-20 and MDA-MB-231. Cell Viability Assay [1] Cell Line: TNBC cell lines (MDA-MB-231, BT-20, 4T1, MDA-MB-468), MCF-7 ( ERBB2 - ), SKBR-3 ( ERBB2 + ) and HEK293T. Concentration: 100 nM and 1000 nM. Incubation Time: 7 days. Result: Equally inhibited the colony formation abilities of several breast cancer cell lines. |
体内活性 | SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases [1]. In general, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC [1]. Animal Model: BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 10 6 cells/ each mouse) [1] Dosage: 30mg/kg. Administration: PO, 3 times a week for 40 days. Result: Tumor allografts grew at a slower rate compared to control groups. Significant inhibition of the number of lung metastases as visualized. |
分子量 | 507.35 |
分子式 | C19H23N7Se2 |
CAS No. | 2403650-93-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SLLN-15 2403650-93-9 Others SLLN 15 SLLN15 Inhibitor inhibitor inhibit